Global pharma market will grow by 5% in 2009: IMS Health

Share this article:

IMS Health has forecasted a 4.5% to 5.5% growth in the global pharmaceutical market during 2009, with dollar amounts exceeding $820 billion.

In the US, the pharma market is predicted to grow by 1% to 2%—$287 billion to $297 billion—slightly less than the 2% or 3% rate previously expected, according to IMS Health's 2009 Global Market Forecast, published today.

So-called “pharmerging markets”, such as China, Brazil, India, South Korea, Mexico, Turkey and Russia, are predicted to show the most growth next year, with numbers reaching $105 to $115 billion combined, or 14% to 15%, according to the data.

Among therapeutic classes, oncologics is expected to grow the most, by 15% to 16% [$48-$52 billion] in 2009, followed by HIV Antivirals at 13% to 14% [$9-$13 billion], and narcotic analgesics, at 12% to 13% [$8-$12 billion].

In other findings, IMS projected only 25 to 30 new chemical entities slated for launch in 2009.  Four or five of those products, in the areas of acute coronary syndrome, diabetes, rheumatoid arthritis and meningitis, could turn out to be blockbusters, the report speculated.

“Pharmaceutical growth next near will hold stead at 2008 levels,” said Murray Aitken, senior vice president, healthcare insight, IMS, in a statement. “The market will continue to contend with a number of forces – among them, the shift in growth from developed countries to emerging ones, specialist-driven products playing a larger role, blockbuster drugs losing patent protection, and the rising influence of regulators and payers on healthcare decisions. Layered on top is the uncertainty in the global economic environment and its effect on demand.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...